US-approved vaccines contain no peanut oil; evidence does not link vaccine ingredients, including aluminum, to peanut allergies, despite social media claims. About 1–2% of Americans have the allergy, the American Academy of Allergy, Asthma & Immunology says.
Some posts also alleged Pfizer was driving peanut-allergy rates to profit from EpiPen sales. Pfizer told AFP it does not hold the EpiPen patent: Mylan held it before merging with Pfizer’s Upjohn division in 2020 to form Viatris. The patent expired in September 2025, meaning generic drugs could enter the market.
Social posts have also cited Adjuvant 65, a peanut-oil-based adjuvant discussed in a 1964 report about a potential flu vaccine that was not licensed for general use; it was never reported as used outside clinical trials. Separately, a 2015 study found that introducing peanuts early reduced the frequency of peanut allergy development in children. The findings prompted US guidelines recommending peanuts when a child starts eating solid foods, rather than waiting until age three.
